Portal vein thrombosis and nodular regenerative hyperplasia associated with the use of bevacizumab and oxaliplatin. Report of one case;Trombosis venosa portal e hiperplasia nodular regenerativa hepática; posible efecto adverso asociado a bevacizumab y oxaliplatino

Revista Medica de Chile

Volumn 141, Issue 10, 2013, Pages 1344-1348

  Fluxá C , Daniela ^a   Salas M , Sebastián ^a   Regonesi M , Carlos ^b   Contreras M , Luis ^b   Wash F , Alex ^b   Silva P , Guillermo ^b  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b CLÍNICA LAS CONDES   (Chile)

Author keywords

Antibodies; Bevacizumab; Focal nodular hyperplasia; Humanized; Hypertension; Monoclonal; Organometallic compounds; Oxaliplatin; Portal

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

AGED; BIOPSY; CASE REPORT; CHEMICALLY INDUCED; COLON TUMOR; HUMAN; HYPERTENSION, PORTAL; LIVER TUMOR; MALE; NODULAR HYPERPLASIA; PORTAL VEIN; SECONDARY; VEIN THROMBOSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COLONIC NEOPLASMS; FOCAL NODULAR HYPERPLASIA; HUMANS; HYPERTENSION, PORTAL; LIVER NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS; PORTAL VEIN; VENOUS THROMBOSIS;

EID: 84893940200     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013001000017     Document Type: Article

References (16)

1. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: Current concepts and management. J Gastroenterol Hepatol 2002; 17 (5): 526-34.
2. Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51 (2): 275-80.
3. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic non cirrhotic portal hypertension. Liver Transpl 2005; 11 (6): 627-34.
4. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44 (1): 7-14.
5. Van den Broek M, Olde S, Driessen A, Dejong C, Bemelmans M. Nodular regenerative hyperplasia secondary to neoadjuvant chemotherapy for colorectal liver metastasis. Case report med. 2009, (2009). Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787019/ [Consultado el 20 de marzo de 2012].
6. Wang HM, Lo GH, Hsu PI, Lin CK, Chan HH, Chen WC, et al. Nodular regenerative hyperplasia of the Liver. J Chin Med Assoc 2008; 71 (10): 523-7.
7. De Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992; 15 (1-2): 256-61.
8. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004; 75 (4): 225-30.
9. Seoane A, Galeras JA, Coll S, Solà R, Bory F. Ascites as the sole clinical manifestation in a patient with nodular regenerative hiperplasia. Gastroenterol Hepatol 2003; 26 (5): 297-9.
10. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22 (6): 1404-12.
11. Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 2010; 8 (1): 102-13.
12. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49 (3): 287-97.
13. Béchade D, Désolneux G, Fonck M, Soubeyran I, Bécouarn Y, Evrard S. Regenerative nodular hyperplasia of the liver related to oxaliplatin-based chemotherapy. Presse Med 2013; 42 (1): 102-7.
14. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56 (4): 430-9.
15. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 2011; 18 (3): 659-69.
16. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110 (12): 2761-7.